- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05231213
Effects of Neuromodulation and Cognitive Training for Suicide in Veterans (ENACTS) (ENACTS)
June 9, 2026 updated by: VA Office of Research and Development
Impaired executive function, such as impaired decision making and impulsivity, has been identified as an important contributor to the transition from suicidal ideation to suicide attempt.
To address the epidemic of Veteran suicide in the United States, this study tests the feasibility, acceptability, and preliminary effectiveness of a five day transcranial direct current stimulation (tDCS) augmented executive functioning training intervention.
This intervention is delivered to high suicide risk inpatients.
The ultimate goal is to reduce future suicide events (ideation, attempts, deaths) and improve quality of life (e.g.
social relationships, health resource utilization).
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55417-2309
- Minneapolis VA Health Care System, Minneapolis, MN
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- currently admitted into the MVAHCS Inpatient Psychiatric Unit
- at a heightened risk for suicide (defined as a positive screen on the VA Comprehensive Suicide Risk Evaluation (CSRE) at intake and/or a suicide attempt within the previous 12 months)
- able to complete procedures and tasks
Exclusion Criteria:
- are unable to provide informed consent as determined by the Modified Dysken Tool
- have moderate/severe cognitive impairment as determined by the Mini-Mental State Examination (score 27)
- have contraindications for tDCS (history of seizures, metallic cranial plates/screws or implanted device, history of eczema on scalp)
- do not have a smartphone or device running Android or Apple iOS with which to download the mPRO EMA app
- have been involuntarily committed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active tDCS
Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
|
Cognitive training concurrent with 2 mAmps of anodal stimulation applied to the left frontal cortex for 20 minutes.
|
|
Sham Comparator: Sham tDCS
Participants will receive 10 sessions of cognitive training concurrent with sham tDCS.
For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down.
This method mimics the initial physical sensation of stimulation, but there is no active current for the remainder of the session.
|
Cognitive training concurrent with sham tDCS (30 secs ramp up/ramp down of current at beginning and end of session).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment Feasibility
Time Frame: 2 years
|
Recruitment feasibility will be demonstrated by successful recruitment of 15 participants per year into the study.
|
2 years
|
|
Intervention Acceptability
Time Frame: 2 months
|
Acceptability of the intervention will be demonstrated by a retention rate of 80% at the 2 month follow-up assessment, and by 70% of participants being able to complete ⅔ of treatment sessions.
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Completion Time of the Groton Maze Task
Time Frame: Change over time from the baseline session through post-intervention, 1 month follow-up, and 2 month follow-up sessions.
|
Differences in magnitude of change in performance on the Groton Maze Task between active and sham tDCS groups from baseline to follow-up sessions.
Outcome score is time to complete task, with longer time indicating worse performance.
|
Change over time from the baseline session through post-intervention, 1 month follow-up, and 2 month follow-up sessions.
|
|
Change in NIH Quality of Life Questionnaire
Time Frame: Change over time from the baseline session through post-intervention, 1 month follow-up, and 2 month follow-up sessions.
|
Differences in magnitude of change in scores on the NIH Quality of Life (QoL) battery in the domains of cognitive, social, emotional, and behavioral abilities between active and sham tDCS groups from baseline to follow-up sessions.
Responses are on a 0-5 Likert scale.
The primary outcome measure is the mean Total score across these domains.
Higher scores indicate better QoL.
|
Change over time from the baseline session through post-intervention, 1 month follow-up, and 2 month follow-up sessions.
|
|
Change in UPPS-P Impulsive Behavior Scale
Time Frame: Change over time from the baseline session through post-intervention, 1 month follow-up, and 2 month follow-up sessions.
|
The UPPS-P assesses impulsive behavior in five domains: Positive Urgency, Negative Urgency, (lack of) Premeditation, (lack of) Perseverance, and Sensation Seeking.
The scale uses a 1 (agree strongly) to 4 (disagree strongly) response format.
The primary outcome measure is the Total score across these domains, calculated as the average of all items in the questionnaire.
Higher scores indicate more impulsive behavior.
|
Change over time from the baseline session through post-intervention, 1 month follow-up, and 2 month follow-up sessions.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Casey S Gilmore, PhD, Minneapolis VA Health Care System, Minneapolis, MN
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 2, 2022
Primary Completion (Actual)
March 31, 2025
Study Completion (Actual)
March 31, 2025
Study Registration Dates
First Submitted
January 28, 2022
First Submitted That Met QC Criteria
January 28, 2022
First Posted (Actual)
February 9, 2022
Study Record Updates
Last Update Posted (Actual)
July 7, 2026
Last Update Submitted That Met QC Criteria
June 9, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D4104-P
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.